Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.

MLA

Md Yusof, Md Yuzaiful, et al. “Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.” Arthritis & Rheumatology (Hoboken, N.J.), vol. 71, no. 11, Nov. 2019, pp. 1812–23. EBSCOhost, https://doi.org/10.1002/art.40937.

APA

Md Yusof, M. Y., Vital, E. M., McElvenny, D. M., Hensor, E. M. A., Das, S., Dass, S., Rawstron, A. C., Buch, M. H., Emery, P., & Savic, S. (2019). Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. Arthritis & Rheumatology (Hoboken, N.J.), 71(11), 1812–1823. https://doi.org/10.1002/art.40937

Chicago

Md Yusof, Md Yuzaiful, Edward M Vital, Damien M McElvenny, Elizabeth M A Hensor, Sudipto Das, Shouvik Dass, Andy C Rawstron, Maya H Buch, Paul Emery, and Sinisa Savic. 2019. “Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.” Arthritis & Rheumatology (Hoboken, N.J.) 71 (11): 1812–23. doi:10.1002/art.40937.